Novel mutations in the CYBB gene causing X-linked chronic granulomatous disease: a case report of 2 patients
Abstract
Introduction: Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency caused by mutations in the NADPH complex characterized by recurrent infections, inflammation and autoimmunity. While autosomal recessive forms exist, X-linked CGD makes up the majority of cases, which is caused by mutations in the CYBB gene. Patients are at high risk for infections with catalase positive bacteria and fungi. The prognosis has improved significantly with improvements in disease detection and management, including prophylactic antibiotic and antifungal therapy. Hematopoietic stem cell transplantation (HSCT) is a curative option for patients with a suitable donor.
Aim: To report the clinical presentation, immune features and genetic mutations in 2 patients with novel mutations in the CYBB gene causing X-linked CGD who underwent HSCT.
Results: Case 1: Patient 1 is a 14-year-old patient who initially presented with disseminated aspergillosis at the age of 3. He was noted to have an abnormal neutrophil oxidative burst index (NOBI) and genetic testing revealed a mutation in the CYBB gene (c.883_87dupGTGGT) consistent with CGD. He successfully underwent HSCT at age 4. At age 10 he developed a primary intracranial rhabdomyosarcoma in the posterior cranial fossa. Case 2: Patient 2 is a 4-year-old male who was worked up for CGD after developing a perianal abscess at 1 month of age followed by Moraxella bacteremia at 2 months of age. He had 2 abnormal NOBIs and genetic testing identified a novel mutation in the CYBB gene that was thought to explain his phenotype (c.941delA). He underwent an HSCT (10/10 HLA matched unrelated donor). Both patients have had normalization of their NOBI post-transplant and remain free of significant infections.
Discussion: We report the clinical presentation, immune features and genetic mutations in 2 patients with novel mutations in the CYBB gene causing X-linked CGD. Identifying pathogenic mutations causing CGD is important for a better understanding of genotype–phenotype associations and disease course in this patient population.
Statement of novelty: We describe 2 pediatric patients diagnosed with X-linked chronic granulomatous disease due to novel mutations in the CYBB gene.
Formats available
You can view the full content in the following formats:
REFERENCES
Arnold D.E. and Heimall J.R. 2017. A review of chronic granulomatous disease. Adv. Ther. 34(12): 2543–2557.
Beauté J., Obenga G., Le Mignot L., Mahlaoui N., Bougnoux M.E., Mouy R., Gougerot-Pocidalo M.A., Barlogis V., Suarez F., Lanternier F., Hermine O., Lecuit M., Blanche S., Fischer A., Lortholary O., and French PID Study Group CEREDIH. 2011. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: A multicenter study in France. Pediatr. Infect. Dis. J. 30(1): 57–62.
Blumental S., Mouy R., Mahlaoui N., Bougnoux M.E., Debré M., Beauté J., Lortholary O., Blanche S., and Fischer A. 2011. Invasive mold infections in chronic granulomatous disease: A 25-year retrospective survey. Clin. Infect. Dis. 53(12): e159–e169.
Falcone E.L. and Holland S.M. 2012. Invasive fungal infection in chronic granulomatous disease: Insights into pathogenesis and management. Curr. Opin. Infect. Dis. 25(6): 658–669.
Fattahi F., Badalzadeh M., Sedighipour L., Movahedi M., Fazlollahi M.R., Mansouri S.D., Khotaei G.T., Bemanian M.H., Behmanesh F., Hamidieh A.A., Bazargan N., Mamishi S., Zandieh F., Chavoshzadeh Z., Mohammadzadeh I., Mahdaviani S.A., Tabatabaei S.A., Kalantari N., Tajik S., Maddah M., Pourpak Z., and Moin M. 2011. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J. Clin. Immunol. 31(5): 792–801.
Jones L.B., McGrogan P., Flood T.J., Gennery A.R., Morton L., Thrasher A., Goldblatt D., Parker L., and Cant A.J. 2008. Special article: Chronic granulomatous disease in the United Kingdom and Ireland: A comprehensive national patient-based registry. Clin. Exp. Immunol. 152(2): 211–218.
Köker M.Y., Camcıoğlu Y., van Leeuwen K., Kılıç S.Ş., Barlan I., Yılmaz M., Metin A., de Boer M., Avcılar H., Patıroğlu T., Yıldıran A., Yeğin O., Tezcan I., Sanal Ö., and Roos D. 2013. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J. Allergy Clin. Immunol. 132(5): 1156–1163.e5.
Kuhns D.B., Alvord W.G., Heller T., Feld J.J., Pike K.M., Marciano B.E., Uzel G., DeRavin S.S., Priel D.A., Soule B.P., Zarember K.A., Malech H.L., Holland S.M., and Gallin J.I. 2010. Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 363(27): 2600–2610.
Magnani A., Brosselin P., Beauté J., de Vergnes N., Mouy R., Debré M., Suarez F., Hermine O., Lortholary O., Blanche S., Fischer A., and Mahlaoui N. 2014. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J. Allergy Clin. Immunol. 134(3): 655–662.e8.
Marciano B.E., Wesley R., De Carlo E.S., Anderson V.L., Barnhart L.A., Darnell D., Malech H.L., Gallin J.I., and Holland S.M. 2004. Long-term interferon-γ therapy for patients with chronic granulomatous disease. Clin. Infect. Dis. 39(5): 692–699.
Marciano B.E., Spalding C., Fitzgerald A., Mann D., Brown T., Osgood S., Yockey L., Darnell D.N., Barnhart L., Daub J., Boris L., Rump A.P., Anderson V.L., Haney C., Kuhns D.B., Rosenzweig S.D., Kelly C., Zelazny A., Mason T., DeRavin S.S., Kang E., Gallin J.I., Malech H.L., Olivier K.N., Uzel G., Freeman A.F., Heller T., Zerbe C.S., and Holland S.M. 2015. Common severe infections in chronic granulomatous disease. Clin. Infect. Dis. 60(8): 1176–1183.
Martire B.Rondelli R.Soresina A.Pignata C.Broccoletti T.Finocchi A.Rossi P.Gattorno M.Rabusin M.Azzari C.Dellepiane R.M.Pietrogrande M.C.Trizzino A.Di Bartolomeo P.Martino S.Carpino L.Cossu F.Locatelli F.Maccario R.Pierani P.Putti M.C.Stabile A.Notarangelo L.D.Ugazio A.G.Plebani A.De Mattia D. IPINET. 2008. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: An Italian multicenter study. Clin. Immunol. 126(2): 155–164.
Matute J.D., Arias A.A., Wright N.A., Wrobel I., Waterhouse C.C., Li X.J., Marchal C.C., Stull N.D., Lewis D.B., Steele M., Kellner J.D., Yu W., Meroueh S.O., Nauseef W.M., and Dinauer M.C. 2009. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40phox and selective defects in neutrophil NADPH oxidase activity. Blood, 114(15): 3309–3315.
Roos D. and de Boer M. 2014. Molecular diagnosis of chronic granulomatous disease. Clin. Exp. Immunol. 175(2): 139–149.
Segal B.H., Leto T.L., Gallin J.I., Malech H.L., and Holland S.M. 2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine, 79(3): 170–200.
The International Chronic Granulomatous Disease Cooperative Study Group. 1991. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324(8): 509–516.
van den Berg J.M., van Koppen E., Ahlin A., Belohradsky B.H., Bernatowska E., Corbeel L., Español T., Fischer A., Kurenko-Deptuch M., Mouy R., Petropoulou T., Roesler J., Seger R., Stasia M.J., Valerius N.H., Weening R.S., Wolach B., Roos D., and Kuijpers T.W. 2009. Chronic granulomatous disease: The European experience. PLoS ONE, 4(4): e5234.
Vignesh P., Rawat A., Kumar A., Suri D., Gupta A., Lau Y.L., Chan K.W., and Singh S. 2017. Chronic granulomatous disease due to neutrophil cytosolic factor (NCF2) gene mutations in three unrelated families. J. Clin. Immunol. 37(2): 109–112.
Winkelstein J.A., Marino M.C., Johnston R.B. Jr., Boyle J., Curnutte J., Gallin J.I., Malech H.L., Holland S.M., Ochs H., Quie P., Buckley R.H., Foster C.B., Chanock S.J., and Dickler H. 2000. Chronic granulomatous disease: Report on a national registry of 368 patients. Medicine, 79(3): 155–169.
Wolach B., Gavrieli R., de Boer M., van Leeuwen K., Berger-Achituv S., Stauber T., Ben Ari J., Rottem M., Schlesinger Y., Grisaru-Soen G., Abuzaitoun O., Marcus N., Zion Garty B., Broides A., Levy J., Stepansky P., Etzioni A., Somech R., and Roos D. 2017. Chronic granulomatous disease: Clinical, functional, molecular, and genetic studies. The Israeli experience with 84 patients. Am. J. Hematol. 92(1): 28–36.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 7 • Number 2 • June 2020
Pages: 61 - 65
History
Received: 2 March 2020
Accepted: 18 April 2020
Accepted manuscript online: 19 May 2020
Copyright
© 2020.
Authors
Competing Interests
We have no conflict of interest to declare.
Funding Information
There was no funding for this project.
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
ShamaSud, EyalGrunebaum, JuliaUpton, and Vy H.D.Kim. 2020. Novel mutations in the CYBB gene causing X-linked chronic granulomatous disease: a case report of 2 patients. LymphoSign Journal.
7(2): 61-65. https://doi.org/10.14785/lymphosign-2020-0005
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
